ApoC1 Antibody (YA2348)
(Synonyms: APO C1; Apo CI; APOC 1; ApoC I; APOC1; APOC1B; ApolipoproteinCI)
Based on 1 Customer Validation
ApoC1 Antibody (YA2348) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoC1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, IP, FC
-
Reactivity :
Human
-
Formulation:
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IP
IP: Immunoprecipitation
|
FC
FC: Flow Cytometry
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:500-1:1000 | 1:50-1:100 | 1:50-1:200 | 1:50 | 1:50-1:100 |
Product Details
ApoC1 Antibody (YA2348) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoC1.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 9 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 9 kDa
A synthesized peptide derived from human Apolipoprotein CI aa1-83/83.
Endogenous
Affinity Purified
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis of extracts from HepG2(lane 2(20ug) and HepG2(lane 3(40ug) using ApoC1 Antibody (HY-P82603) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P83730, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. -
Immunohistochemical analysis of paraffin-embedded human liver cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human thyroid cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human oral cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human throat cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human breast cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human testis cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human renal cancer tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human colon tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunohistochemical analysis of paraffin-embedded human placenta tissue using ApoC1 Antibody (HY-P82603, 1/100). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX. -
Immunocytochemistry analysis of Hela cells labeling ApoC1 with ApoC1 Antibody (HY-P82603) at 1/100 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with ApoC1 Antibody (HY-P82603) at 1/100 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4 ℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L（HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue). -
Immunocytochemistry analysis of Hela cells labeling ApoC1 with ApoC1 Antibody (HY-P82603) at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with ApoC1 Antibody (HY-P82603) at 1/50 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4 ℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L（HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
Background
-
Function
Apolipoprotein C-I (apoC-I) is a small exchangeable apolipoprotein primarily associated with high-density lipoproteins (HDL) and triglyceride-rich lipoproteins, where it functions as a key regulator of lipoprotein metabolism and lipid transport[1][2]. Mechanistically, apoC-I modulates several pathways that control plasma lipid homeostasis by inhibiting lipoprotein lipase (LPL) -mediated triglyceride hydrolysis, reducing the interaction of very-low-density lipoproteins (VLDL) with lipoprotein receptors, and suppressing cholesteryl ester transfer protein (CETP) activity, thereby influencing both triglyceride and cholesterol flux between lipoprotein particles[1][2]. Through these actions, apoC-I contributes to the regulation of HDL remodeling, VLDL clearance, and overall lipid distribution in circulation[1]. Beyond lipid metabolism, apoC-I has been implicated in inflammatory and immune processes, linking dyslipidemia with cardiovascular and metabolic disease pathogenesis[2][3]. Experimental studies further demonstrate that apoC-I can modulate host responses to bacterial lipopolysaccharide and influence inflammatory signaling in disease-relevant models[3]. Compared with related apolipoprotein C family members, apoC-I is distinguished by its potent inhibition of CETP and its ability to interfere with apolipoprotein E-dependent lipoprotein receptor interactions, highlighting a unique regulatory role in lipoprotein trafficking[2][1]. Because of these properties, apoC-I is widely used as a mechanistic target in studies of hypertriglyceridemia, atherosclerosis, diabetes-associated lipid abnormalities, and lipoprotein metabolism, while genetic and transgenic models continue to provide valuable platforms for investigating its biological functions and therapeutic relevance[1][2][4].
-
Subcellular Localization
Secreted
-
Expression
Tissue_specificity:Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen -
SwissProt ID
-
Synonyms
APO C1; Apo CI; APOC 1; ApoC I; APOC1; APOC1B; ApolipoproteinCI
-
Research Field
Cardiovascular
Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
[1]. Rouland A, et al. Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review. Cardiovasc Diabetol. 2022 Dec 5;21(1):272. [Content Brief]
[2]. Fuior EV, et al. Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond. Int J Mol Sci. 2019 Nov 26;20(23):5939. [Content Brief]
[3]. Berbée JF, et al. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J Lipid Res. 2010 Jul;51(7):1943-52. [Content Brief]
[4]. Jong MC, et al. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. The Biochemical Journal. 1997 Jan;321 ( Pt 2):445-450. [Content Brief]
Powered by Bioz
